Bifogade filer
ENG - PM Aktiemarknadens offentligörande 251020
Kurs
+3,40%
Likviditet
7,42 MSEK
Kalender
| Est. tid* | ||
| 2026-06-04 | 07:00 | Bokslutskommuniké 2026 |
| 2026-03-05 | - | Kvartalsrapport 2026-Q3 |
| 2025-11-21 | - | Kvartalsrapport 2026-Q2 |
| 2025-11-10 | - | Extra Bolagsstämma 2025 |
| 2025-10-29 | - | Årsstämma |
| 2025-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2025-09-01 | - | Kvartalsrapport 2026-Q1 |
| 2025-06-03 | - | Bokslutskommuniké 2025 |
| 2025-03-03 | - | Kvartalsrapport 2025-Q3 |
| 2024-12-04 | - | Kvartalsrapport 2025-Q2 |
| 2024-09-26 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2024-09-25 | - | Årsstämma |
| 2024-08-29 | - | Kvartalsrapport 2025-Q1 |
| 2024-05-30 | - | Bokslutskommuniké 2024 |
| 2024-02-29 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-04 | - | Kvartalsrapport 2024-Q2 |
| 2023-10-04 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2023-09-27 | - | Årsstämma |
| 2023-08-31 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-08 | - | Bokslutskommuniké 2023 |
| 2023-03-01 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-01 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-03 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2022-09-28 | - | Årsstämma |
| 2022-08-31 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-10 | - | Bokslutskommuniké 2022 |
| 2022-03-02 | - | Kvartalsrapport 2022-Q3 |
| 2021-12-02 | - | Kvartalsrapport 2022-Q2 |
| 2021-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2021-09-02 | - | Kvartalsrapport 2022-Q1 |
| 2021-05-31 | - | Bokslutskommuniké 2021 |
| 2021-03-03 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-02 | - | Kvartalsrapport 2021-Q2 |
| 2020-09-30 | - | Årsstämma |
| 2020-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2020-08-24 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-08 | - | Bokslutskommuniké 2020 |
| 2020-04-20 | - | Extra Bolagsstämma 2020 |
| 2020-03-02 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-02 | - | Kvartalsrapport 2020-Q2 |
| 2019-09-30 | - | Årsstämma |
| 2019-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2019-09-02 | - | Kvartalsrapport 2020-Q1 |
| 2019-06-10 | - | Bokslutskommuniké 2019 |
| 2019-03-04 | - | Kvartalsrapport 2019-Q3 |
| 2018-12-17 | - | Kvartalsrapport 2019-Q2 |
| 2018-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2018-09-24 | - | Årsstämma |
| 2018-09-24 | - | Kvartalsrapport 2019-Q1 |
| 2018-06-25 | - | Bokslutskommuniké 2018 |
| 2018-03-26 | - | Kvartalsrapport 2018-Q3 |
| 2017-12-18 | - | Kvartalsrapport 2018-Q2 |
| 2017-09-25 | - | Årsstämma |
| 2017-09-25 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-30 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
The Council emphasizes that the obligation to work toward the fulfillment of stated conditions is particularly strong when a principal shareholder has given an irrevocable undertaking to accept the offer and, at the end of the acceptance period, it is clear that the shares have not been tendered. According to the Council, at a minimum the bidder should have made direct contact with the principal shareholder or the shareholder’s legal counsel to allow the undertaking to be fulfilled.
The Council concludes that the measures taken by the bidder did not meet this requirement and that the bidder’s conduct therefore contravened the takeover rules and good market practice. Integrum welcomes the Council’s clarification of the application of the takeover rules in these respects. The statement aligns with the assessment that Integrum set out in its press releases of September 17 and 18, 2025, namely that more could and should have been done to satisfy the completion condition, including that the bidder should have contacted the principal shareholder directly or delayed the announcement of the outcome to allow correction of formal errors.
The Board would like to emphasize that the Swedish Securities Council’s statement does not change Integrum’s operations or financial position. The company continues to pursue its strategy and operational development with undiminished focus.
Integrum AB
The Board of Directors
For more information, please contact:
Martin Hillsten, CEO
Email: martin.hillsten@integrum.se
Tel: +46 (0)73 355 28 32
Certified Adviser
The company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Integrum
Integrum is a publicly traded company (Nasdaq First North Growth Market: INTEG B) based outside Gothenburg, with a U.S. subsidiary in San Francisco. Since 1990, the company’s OPRA® Implant System has helped improve the quality of life for hundreds of amputees by attaching a prosthesis directly to the skeleton and musculoskeletal system, eliminating the need for a traditional socket prosthesis. The system, based on osseointegration, offers improved mobility and function, increased comfort, reduced pressure, and stable fixation. The OPRA® Implant System received approval from the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for amputees in the United States. Integrum continues to conduct research and develop tailored medical device solutions in close collaboration with researchers and clinicians.